Novelty:
Five HOXB13 markers (G84E, L144P, Y88D, G216C, R229G) for identifying men with high risk of developing early-onset and hereditary prostate cancer.
Value Proposition:
Currently, there are no reliable genetic markers to assess risk for prostate cancer and the PSA test is known to lead to over-diagnosis of men with prostate cancer. To address this issue we have identified and validated markers that are associated with a 5 to 6 fold increase in prostate cancer risk. Studies were performed in a large international sample of prostate cancer families and several peer-reviewed studies have confirmed the strong correlation of these markers with increased prostate cancer risk in men. Additional advantages of this discovery include:
• Cheek swabs or blood tests can be used detect these markers • Markers can be detected using standard sequencing technologies • Better prognosis and early detection of prostate cancer
Looking for Partners:
To develop and commercialize the technology as a diagnostic test for prostate cancer.
Stage of Development:
Pre-Clinical
Data Availability:
Data validated with patient samples.
Publications/Associated Cases:
N Engl J Med 2012; 366:141-149. Hum Genet. 2013 Jan;132(1):5-14. doi: 10.1007/s00439-012-1229-4.
US 20140315746
